Names and pronunciation
(full-vess′trant) Faslodex
PDF page 608
Loading InternPractice…
Drug reference
(full-vess′trant) Faslodex
PDF page 608
Func. class.: Antineoplastic
PDF page 608
Chem. class.: Estrogen-receptor antagonist
PDF page 608
ACTION: Inhibits cell division by competitive binding to cytoplasmic estro- gen receptors, downregulates estrogen receptors
PDF page 608
USES: Advanced breast carcinoma in estrogen-receptor-positive patients (usu- ally postmenopausal)
PDF page 608
CONTRAINDICATIONS: Preg- nancy, breastfeeding, children, hypersen- sitivity Precautions: Hepatic disease, jaundice, thrombocytopenia, biliary tract disease, coagulopathy
PDF page 608
SIDE EFFECTS CNS: Headache, depression, dizziness, insomnia, paresthesia, anxiety GI: Nausea, vomiting, anorexia, consti- pation, diarrhea, abdominal pain, hepati- tis, hepatic failure, hyperbilirubinemia HEMA: Anemia INTEG: Rash, sweating, hot flashes, inj site pain MS: Bone pain, arthritis, back pain RESP: Pharyngitis, dyspnea, cough SYST: Angioedema
PDF page 609
INTERACTIONS Increase: Bleeding—anticoagulants, do not use concurrently Drug/Lab Test Increase: LFTs
PDF page 609
DOSAGE AND ROUTES • Adult: IM 500 mg as 2-, 5-mL injec- tions on days 1, 15, 29 and monthly thereafter
PDF page 609
Available forms: Inj 50 mg/mL
PDF page 609
Administer: IM route • IM 5 mL give one inj in each buttock slowly, over 1-2 min • Antiemetic 30-60 min before product to prevent vomiting prn • Store in refrigerator; protect from light
PDF page 609
Assess: • For anticoagulant use • For side effects; report to prescriber • Pregnancy/breastfeeding: Obtain a pregnancy test within 7 days of first dose, have patient use contraception during and for 1 yr after last dose, do not breastfeed
PDF page 609
Evaluate: • Therapeutic response: decreased tu- mor size, spread of malignancy
PDF page 609
CLINICAL CONSIDERATIONS
PDF page 609
Patient and caregiver information: • To report any complaints, side effects to prescriber • To report vaginal bleeding immediately • That tumor flare (increase in size of tumor, increased bone pain) may occur, will subside rapidly; that analgesics may be taken for pain • That premenopausal women must use mechanical birth control because ovula- tion may be induced; not to breastfeed • To use contraception during and for 1 yr after last dose to prevent pregnancy F
PDF page 609
PHARMACOKINETICS Half-life 40 days, metabolized by CYP3A4, excretion in feces 90%
PDF page 609
• Adult: IM 500 mg as 2-, 5-mL injec- tions on days 1, 15, 29 and monthly thereafter
PDF page 609